Management of diabetic nephropathy.
Foggensteiner
L
L
Dialysis Centre, Box 118 Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. lukasfoggensteiner@ntlworld.com
Mulroy
S
S
Firth
J
J
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000628:therapy; D003928:Diabetic Nephropathies / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000628:therapy; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin